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Lately, many physicians have been saying they've become 
disillusioned with the RBRVS. They don't believe the physi-
cian payment reform will bring gains for their undervalued 
evaluation and management services. They don't trust the fed-
eral government to live up to its end of the bargain. However, 
no one should write off the RBRVS. As can be seen from the 
text below, RBRVS will protect undervalued evaluation and 
management services in an era of medicare budget-cutting; it 
will introduce fairness and rationality into the Medicare pay-
ment system; it will provide a basis for arguing against unfair 
cuts in reimbursement (such as the recent ban on payment for 
most EKG interpretations) and it will bring the profession 
together to fight against any further cuts in the Medicare pro-
gram. 
When the Resource-Based Relative Value Scale first came 
onto the health policy scene, physicians supported it because 
it would introduce fairness and rationality into the Medicare 
payment system, unite the medical profession, and, most of 
all, because it would be good for patients. But lately, I've been 
hearing many of my colleagues say they've become disillu-
sioned with the RBRVS's implementation- they don't trust 
the federal government to live up to its end of the bargain. 
Well, I don't trust the federal government to live up to its 
bargain, either- at least not without concentrated pressure on 
it to do so. However, I don't think the medical profession 
should write off the RBRVS. Despite many problems - some 
immediate and some potential - it still will do what it was 
intended to do. 
For instance, under the RBRVS, relative values are expect-
ed to increase substantially for most evaluation and manage-
ment (ElM) services. Skeptics have suggested that the RBRVS 
will be used only to cut surgical values -and fees. New esti-
mates show, however, that the RBRVS will increase relative 
values for ElM services by 30% on average, and that, as a 
result, Medicare payments for these services will increase sub-
stantially above 1991 payments under a "budget neutral" 
RBRVS fee schedule. 
Better yet, the RBRVS protects undervalued evaluation and 
management services provided by all physicians even when 
the budget is cut. Consider what would happen to a $30 office 
visit from 1991 to 1996 in a purely hypothetical scenario in 
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which fees normally would have been given a 15% inflation 
increase, but Congress cuts payments 10% below inflation. In 
1996, that same office visit fee would total $31.05 without the 
RBRVS. With the protected 30% gain for E/M services 
expected under the RBRVS, it would total $40.36. Especially 
in this budget-cutting climate, the RBRVS will protect fees for 
the E/M services all physicians provide. 
Exactly what effect there will be on an individual's practice 
depends on several factors, however. Because of elimination 
of geographic differentials and limits on balance billing, for 
some there will be no actual gain (or even a reduction) for 
ElM services. Where physicians practice, how often they 
accept assignment, how much they charge in excess of Medi-
care's "approved amount" for unassigned claims, and their 
mix of services, will determine the effect on their practices. 
But regardless of each individual's gain or loss, the RBRVS 
will enhance payments overall for physicians' ElM services 
compared with what would have been. 
Another benefit is that the RBRVS allows physicians to 
unite for a fair conversion factor and to oppose further cuts in 
the Medicare program, rather than engaging in internal squab-
bling. The conversion factor that makes the RBRVS into a real 
fee schedule applies to all physician services. That means the 
entire profession has a stake in making sure it's fair and an 
incentive to work together to stave off future Medicare cuts. 
In fact, every medical group that testified before the Physician 
Payment Review Commission (PPRC) last December, includ-
ing the American Medical Association, the American Society 
of Internal Medicine, the American Academy of Family 
Physicians and the American College of Surgeons, opposed 
HCFA's proposal to lower the conversion factor. HCFA has 
indicated it will assume volume will increase and that it will 
set the conversion factor lower to make up for that assumed 
increase. 
The RBRVS also provides a basis for opposing unfair cuts 
in specific procedures. For example, the profession can argue 
that the ban on reimbursement for most EKG interpretation is 
contrary to the RBRVS, because the study said the service 
indeed has a value. The influential PPRC agrees, giving the 
profession a real opportunity to get this cut reversed. Without 
the RBRVS, it would have been far more difficult to make that 
case. 
Continued support for the RBRVS allows the profession to 
be for- not just against- something. If it wasn't for the 
medical profession's support for the RBRVS, we'd all be 
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AXID ® (nizatidine capsules) 
B~f Summary. Consu~ the package insert for complete prescribing information. 
lrul1cati0lls arul Usage: 1. Active duodenal ulcer- for up 1o 8 weeks of trealment. Most 
patients heal within 4 weeks. 
2. Maintenance therapy- for healed duodenal ulcer patienls at a reduced dosage 
of 150 mg h.s. The consequences of therapy with Axid for longer than 1 year 
are not known. 
Contraind~ations: Known hypersensitivity to the drug. Because cross sen,;uvrty in 
this class of compounds has been observed, H2-receptor antagonists, induding Axid, 
should not be administered to patients with a history of hypersensitivity to other 
H2-receptor antagonists. Precautions: Generaf-1. Symptomatic response to nizatidine therapy does not 
preclude the presence of gastric malignancy. 
2. Oosage sllould be reduced in patienls with motien!te to severe renal insufficoncy. 
3. In patients with norma! rena! function and uncomplicated hepatic dysfunction, 
the disposition of nizatidine is similar to that in normal subjects. 
labomtoty Tests-False-positive tests for urobilinogen with Muffisllx• may occur 
dunngtllerapy. 
Drug Interactions-No interactions have been observed with theophylline, 
chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin. Axid does not inhibit 
tile cytochrome P-450 enzyme system; therefore, drug interactions mediated by 
inhibition of hepatic metabolism are not expected to occur_ In patients given very 
high doses {3,900 mg) of aspirin daily, increased serum salicylate levels were seen 
when nizatidine, 150 mg b.i.d., was administered concurrently. 
Carcinogenesis, Mutagenesis, Impairment ol Femli/y-A 2-year oral carcinogenicity 
study in ra~ with doses as high as 500 rnglt<glday (about 80 times the recommended 
daily therapeutic dose) showed no evidence of a carcinogenic effect There was a 
dose-related increase in the density of enterochromaffin-!ike (ECL) cells in the gastric 
oxyntic mucosa In a 2-year study in mice, there was no evidence of a carcinogenic 
effect in male mice, although hyperplastic nodules of the liver were increased in the 
high-dose males as compared with placebo. Female mice given the high dose of Axid 
(2,000 mglkglday, about 330 times the human dose) sllowed marginal~ statistically 
significant increases in hepatic carcinoma and hepatic nodular hyperplasia with no 
numerical increase seen in any of the other dose groups. The rate of hepatic carcinoma 
in the high-dose animals was within the historical control limits seen for the strain 
of mice used. The female mice were given a dose larger than the maximum tolerated 
dose, as indicated by excessive (30%) weight decrement as compared with concurrent 
controls and evidence of mild liver injury (transaminase elevations). The occurrence of 
a marginal finding at high dose only in animals given an excessive and somewhat 
hepatotoxic dose, with no evidence of a carcinogenic effect in rats, male mice, and female 
mice (given up to 360 mgfkg/day, about 60 times the human dose), and a negative 
mutagenicity battery are not considered evidence of a carcinogenic potential for Axid. 
Axid was not mutagenic in a battery of tests performed to evaluate its potential 
genetic toxicity, including bacterial mutation tests, unscheduled DNA synthesis, sister 
chromatid exchange, mouse lymphoma assay, chromosome aberration tests, and a 
micronucleus test 
In a 2-generation, perinatal and postnatal fertility study in rats, doses of nizatidine 
up to 650 mg/kg/day produced no adverse effects on the reproductive performance 
of parental animalsortheirprogeny. 
Pregnancy- Teratogenic E//ec~-Pregnancy Ca/egory C-Oral reproduction studies 
in rats at doses up to 300 times the human dose and in Dutch Belted rabbits at 
doses up to 55 times the human dose revealed no evidence of impaired fertility or 
teratogenic effect but at a dose equivalent to 300 times the human dose, treated rabbits 
had abortions, decreased number of live fetuses, and depressed fetal weights. On 
intravenous administration to pregnant New Zealand White rabbits, nizatidine at 
20 mg!kg produced cardiac enlargement coarctation of the aortic arch, and cutaneous 
edema in 1 fetus, and at 50 mgfkg, it produced ventricular anomaly, distended 
abdomen, spina bifida, hydrocephaly, and enlarged heart in 1 fetus. There are, 
however, no adequate and well-controlled studies in pregnant women. n is also not 
known whether nizatidine can cause fetal harm when administered to a pregnant 
woman or can affect reproduction capacity. Nizatidine should be used during pregnancy 
only if the potential benefit justifies the potential risk to the fetus. 
Nursing Mothers-Studies in lactating women have shown that 0.1% of an oral 
dose is secreted in human milk in proportion to plasma concentrations. Because of 
growth depression in pups reared by treated lactating rats, a decision should be 
made whether to discontinue nursing or the drug, taking into account the importance 
of the drug to the mother. 
Pediatric Use-Safety and effectiveness m children have not been established. 
Use in Elderly Patients-Healing rates in elderly patients were similar to those 
in younger age groups as were the rates of adverse events and laboratory test 
abnormalities. Age alone may not be an important factor in the disposition of 
nizatidine. Elder!ypatientsmayhavereducedrenalfunction. 
Adverse ReactiOns: Clinical trials of varying durations induded almost 5,000 patienls. 
Among the more COOlman adverse events in domestic placebo-controlled trials of 
over 1,900 nizatidine patients and over 1,300 on placebo, sweating (1% vs 0.2%), 
urticaria (0.5% vs <0.01%), and somnolence (2.4% vs 1.3%) were significantly 
more common with nizatidine. n was not possible to determine whether a variety of 
less common events were due to the drug. 
Hepatic-Hepatocellular injury (elevated liver enzyme tests or alkaline phosphatase) 
possibly or probably related to nizatidine occurred m some patients. In some cases, 
there was marked elevation (>500 lUll) in SGOT or SGPT and, in a single instance, 
SGPT was >2,000 lUlL The mcidence of elevated liver enzymes overall and 
elevations of up to 3 times the upper limit of normal, however, did not significantly 
differfromthatinp!acebopatlents.AIIabnormalitieswerereversibleafterdiscontinuation 
of Axid. Since market introduction, hepatitis and jaundice have been reported. Rare 
cases of cholestalic or mixed hepatocellular and cholestatic injury with jaundice 
have been reported with reversal of the abnormalities after discontinuation of Axid. 
Cardiovascular- In clinical pharmacology studies, short episodes of asymptomatic 
ventricular tachycardia occurred in 2 individuals administered Axid and in 3 
untreated subjects. 
CNS-Rare cases of reversible mental confusion have been reported. 
Endocnne-Chnica! pharmacology studtes and controlled clinical tnals showed no 
evidence of antiandrogenic activity due to nizatidine. Impotence and decreased libido 
were reported with equal frequency by patients on nizatidine and those on placebo. 
Gynecomastia has been reported rarely. 
Hematologic-Fatal thrombocytopenia was reported in a patient treated with 
nizatidine and another H2-receptor antagonist. This patient had previously experienced 
~rombocytopenia while ta~ng other drugs. Rare cases of ~rombocytopen~ purpura 
have been reported 
Integumental-Sweating and urticaria were reported significantly more frequently 
m nizatidine- than m placebo-treated patients. Rash and exfoliative dermatitis were 
also reported. 
Hypersensitivity-As with other H2-receptor antagomsts, rare cases of anaphylaxis 
fol!owmg mzatidme admmtstratron have been reported. Rare epJsodes of hypersensmvrty 
reactions (eg, broochospasm, oryngeal edema, rash, and eosmopiJW•I have been reported. 
Other-Hyperuricemia unassociated with gout or nephrolithiasis was reported. 
Eosmophiha, fever, and nausea related to nizatidine have been reported. 
Overdosage: Overdoses of Axid have been reported rarely. If overdosage occurs, 
activated charcoal, emesis, or lavage should be considered along with climcal 
monitoong and supportive therapy. Renal dialysis does not substantially mcrease 
clearance of mzatidine due to 1ts large volume of distnbution 
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worse off. No one can say that change won't be coming. 
Those who don't like the RBRVS and the limits on balance 
billing should consider the alternatives: mandatory assign-
ment, MD-DRGs, and fees set by the government without any 
professional input. The RBRVS gives the profession a voice, 
and it enables us to ward off more objectionable measures. 
Finally and most importantly, the RBRVS is good for our 
patients. It will increase the emphasis on preventive care and 
on evaluating and managing their treatment, and decrease the 
emphasis on costly high-tech services. It also will help 
improve access to care in underserved rural areas. 
So you see, to paraphrase Mark Twain, reports of the death 
of the RBRVS are greatly exaggerated. But medicine can't 
rely on trust that everything will turn out okay. We must fight 
to preserve the promise of physician payment reform. 
That means opposing policies that will undermine the 
RBRVS (such as a behavioral assumption that would lower 
the fee schedule conversion factor). It means working to 
change policies- such as the ban on reimbursement for EKG 
interpretation - that give with one hand and take away with 
the other. And it means supporting further changes that will 
make the system even better. 
The RBRVS unites physicians under one fair and rational 
payment system to fight future detrimental budget cuts in 
Medicare. Lawmakers faced with a divided house of medicine 
easily can use that division to cut Medicare payments even 
further. But if they're faced with a profession that's united 
under the RBRVS, it won't be easy. 
Support for the RBRVS has been right for our profes-
sion and for our patients. The RBRVS will protect underval-
ued evaluation and management services in an era of Medi-
care budget cutting, increase access and the emphasis on pre-
ventive care for patients, and introduce fairness into the Medi-
care payment system. But we must fight together- as a pro-
fession to make sure it is implemented in the way Congress 
intended. 
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